Cadrenal Therapeutics Inc
Research Cadrenal Therapeutics Inc (CVKD) on Bullrun: market cap USD 4.71M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCVKD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.71M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 11.89M
- Free cash flow-USD 3.00M
Valuation Snapshot
latest market cap is USD 4.71M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 13.24M | -USD 12.61M | n/a | -6.64 | USD 4.01M | n/a | USD 2.74M |
| FY2024 | USD 0 | -USD 10.65M | -USD 7.36M | n/a | -8.73 | USD 10.02M | USD 0 | USD 7.44M |
| FY2023 | n/a | -USD 8.36M | -USD 3.53M | n/a | -9.29 | USD 8.40M | USD 21.35K | USD 7.69M |
| FY2022 | n/a | -USD 6.71M | -USD 1.21M | n/a | -0.85 | USD 32.59K | USD 597.07K | -USD 5.55M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.71M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 15.85M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 25.83M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 9.64M | n/a | n/a | n/a |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2025 | 16.5 USD |
| FY2024 | 16.5 USD |
About Cadrenal Therapeutics Inc
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cadrenal Therapeutics Inc's market cap?
Cadrenal Therapeutics Inc's market capitalization is USD 4.71M.
What does Cadrenal Therapeutics Inc do?
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions.